NEW YORK, April 18, 2012 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Catalyst Health Solutions, Inc. ("Catalyst" or the "Company") (NASDAQ: CHSI) concerning the proposed acquisition of the Company by SXC Health Solutions ("SXC") in a transaction valued at approximately $4.4 billion.
On April 18, 2012, it was announced that Catalyst and SXC have entered into a definitive agreement pursuant to which SXC will acquire Catalyst. Under the agreement, Catalyst shareholders will receive $28.00 in cash and 0.6606 shares of SXC stock per Catalyst share held, for an approximate combined value of $81.02 per Catalyst share.
Our investigation concerns whether the Catalyst board of directors is fulfilling its fiduciary duties, maximizing the value of the Company, disclosing all material benefits and costs, and obtaining full and fair consideration for Company shareholders.
If you own Catalyst shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:
Benjamin Sachs-Michaels Robert I. Harwood, Esq. Harwood Feffer LLP 488 Madison Avenue New York, New York 10022 Phone Numbers: (877) 935-7400 (212) 935-7400 Email: [email protected] Website: http://www.hfesq.com
Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.